Objectives: To compare the concordance of ceftaroline MIC values by reference broth microdilution (BMD) and Etest (bioMérieux, France) for MSSA and MRSA isolates obtained from PREMIUM (D372SL00001), a European multicentre study.
Introduction
Ceftaroline is a new cephalosporin with broad activity against common Gram-positive and Gram-negative pathogens including MRSA. 1, 2 It has proved superior to vancomycin plus aztreonam in complicated skin and soft tissue infections (cSSTI) and to ceftriaxone in community-acquired pneumonia (CAP). 1 -3 On the basis of these trials, ceftaroline, administered as its fosamil ester, was approved for treatment of these infections by the US FDA in October 2010, 4 and by the EMA in August 2012. 5 EUCAST categorizes Staphylococcus aureus with ceftaroline MICs of ≤1 mg/L as susceptible and those with MICs .1 mg/L as resistant. 6 This might present a detection challenge, because the 'tail' of the ceftaroline MIC distribution for MRSA extends to 2 mg/L. 7 It was shown previously that routine diagnostic laboratories, at least in the UK, 8 are poorly able to distinguish isolates with MICs .1 mg/L from more susceptible organisms using either disc or gradient tests, though better discrimination was achieved using discs in a study in Sweden. 9 In the present analysis we compare Etest versus standard broth microdilution (BMD) for ceftaroline MIC determination. Moreover, we sought to examine whether discrimination of isolates with MICs of 2 mg/L was achieved with these methods. This analysis was undertaken in the course of PREMIUM (D372SL00001), a multicentre European survey that evaluated the activity of ceftaroline.
Materials and methods

Clinical isolates
Consecutive clinical isolates from cSSTI and CAP in patients aged ≥18 years were collected from February to May 2012 at 58 laboratories in: Belgium (10 sites), Italy (16), Portugal (6), Spain (15), Switzerland (2) and the UK (9) . For CAP, samples were taken from sputum, bronchoalveolar lavage (BAL), tracheal/bronchial aspirate, bronchoscopic protected brush specimen, blood culture or pleural fluid. For cSSTI, fine needle aspiration puncture/biopsy was preferred, although good-quality swabs were also permitted. Collected isolates were then sent to the central laboratory in the corresponding country, along with information about the microorganism and the source patient, recorded in an electronic Case Report Form. The study was approved by the Ethics Committee (ref. 336/1, Ramó n y Cajal University Hospital, Madrid, Spain).
Antimicrobial susceptibility testing
Organisms were tested for susceptibility to ceftaroline by BMD and Etest (bioMérieux, France) at six central laboratories. Each of these laboratories tested isolates from their respective countries using the same methods and quality control S. aureus ATCC 25923 isolate. BMD MICs were determined using Sensititre plates (ThermoFisher Scientific, UK) with Mueller -Hinton broth, as indicated by both EUCAST and CLSI specifications. 6, 10, 11 The concentration range for ceftaroline was 0.008 -4 mg/L. Etest had ceftaroline gradients from 0.002 and 32 mg/L, which were used on Mueller-Hinton agar from the laboratories ′ local suppliers. MICs were analysed with respect to EUCAST criteria, with ≤1 mg/L considered susceptible and MIC .1 mg/L resistant. 6 
Data analysis
S. aureus isolates with MIC values obtained by both methods were included in the analysis. Etest MICs were rounded up to the next concentration of the standard doubling dilution scale when necessary. Concordance criteria included: essential agreement (EA) (i.e. agreement within one doubling dilution between methods), categorical agreement (CA) (agreement as susceptible or resistant), major errors (susceptible by BMD but resistant by Etest) and very major errors (VMEs; resistant by BMD but susceptible by Etest).
12 MIC distributions were compared by regression of log MICs using WHONET software. 13 Repetitive study: selective retesting of clinical isolates Initial analyses revealed MICs .1 mg/L by BMD for 26 MRSA isolates. To confirm these values, 21 of these isolates were retested twice by both methods at the three central laboratories in Italy, Spain and the UK, with results recorded by different operators. The remaining five isolates were not available for reanalysis. Additionally, two isolates with MIC 1 mg/L were also retested as controls. 
Results
MIC agreement: BMD versus Etest
Error rates
All MSSA isolates were found susceptible by both BMD and Etest (Table 1) . Among MRSA isolates, 17/406 (4.2%) were counted as resistant by Etest but susceptible by BMD or vice versa. Crucially, among the 26 isolates found resistant by BMD, with MICs of 2 -4 mg/L, 12 were found susceptible (i.e. MIC ≤1 mg/L) by Etest, equating to a very major error rate of 46.2%. The major error rate (susceptible by BMD but resistant by Etest) was much lower, at 5/380 cases (1.3%).
Repetitive study
To further examine reproducibility and discrimination for isolates with raised MICs, we selected 21 isolates with MIC 2 mg/L and two with MIC 1 mg/L by BMD in the original analysis (Table 1) (Table 1) .
Discussion
Ceftaroline is one of a very few broad-spectrum agents with a spectrum including MRSA (the only others are tigecycline and ceftobiprole), and it is important that laboratories are able to test it reliably. Although automated systems or disc testing are the routine methods of susceptibility testing in most diagnostic laboratories, gradient strips such as Etest are widely used for lowthroughput, high-precision work, when a more precise estimate of the MIC is sought.
This study was therefore designed to compare Etest and standard BMD methods for ceftaroline MIC determination, and sought to assess whether Etest could reliably detect S. aureus isolates with MICs .1 mg/L, which count as resistant according to EUCAST criteria, 6 though as intermediate on CLSI and FDA breakpoints. 10 This detection is inherently challenging, as MICs for these isolates are almost invariably 2 mg/L (as in 25/26 cases here, Figure 1 ), and they might represent the tail of a normal distribution for MRSA isolates with WT PBP2a protein, 7 though recent whole-genome sequence analysis shows that isolates with ceftaroline MICs of 2 -4 mg/L often have amino acid substitutions in the non-penicillin-binding domain of PBP2a. Etest versus broth microdilution for ceftaroline MIC determination Cantó n et al.
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Such substitutions are prevalent in, for example, South Korea, China and Thailand. 15 In general, agreement between Etest and BMD MIC results is good, although there are some systematic biases toward higher or (mostly) lower MICs by Etest for particular microorganismantibiotic combinations. 16 -19 In the current study, Etest returned slightly lower MICs than BMD for S. aureus and, although EA and CA between the two methods exceeded 95%, almost half (12/26, 46.2%) of the MRSA isolates found resistant by BMD were scored as susceptible, with MICs of 1 mg/L, by Etest in the original testing. These findings, which were based on pooled results from the six national laboratories, led us to retest 23 isolates, 21 of them with initial MICs of 2 mg/L by BMD, at three central laboratories. Each site tested each isolate twice by each method, with different staff scoring the Etest and broth results. BMD MICs of 2 mg/L were found for 19 isolates in all repeats at all sites, supporting the view that their resistance was 'real'. For 17, Etest MICs of .1.5 mg/L (2 mg/L after rounding) were obtained in a majority of the seven tests performed per isolate. This experience suggests that, with careful reading, it is possible to reduce the proportion of cases where low-level ceftaroline resistance is missed by Etest, thus decreasing potential VME results. Performance may also be improved if multiple Etests are run per isolate, albeit at additional cost of time and materials. Reproducibility of MIC values with gradient tests from other manufacturers also showed no clear distinction between isolates with MIC results of 1 and 2 mg/L. 19 In conclusion, ceftaroline achieves robust in vitro antibacterial activity against the great majority of S. aureus from cSSTI and CAP in the European countries surveyed. Nevertheless, MICs of 2 mg/L, signifying resistance on EUCAST criteria or intermediate status on CLSI and FDA criteria, are seen for a small minority of isolates by BMD. Detection of these non-susceptible organisms by Etest is challenging, even under reference laboratory testing, as here, requiring experience and diligence on the part of the individual reader. We cannot rule out heteroresistance and/or protein amino acid substitutions in the non-penicillin-binding domain of PBP2a of these isolates. 14, 15, 20 
